Every year, 500,000 people in the United States have an ST-elevationmyocardial infarction.1 Timely and effective reperfusion withthe use of either primary percutaneous coronary intervention(PCI) or thrombolytic therapy remains the most effective treatmentstrategy for limiting the size of the myocardial infarct, preservingleft ventricular ejection fraction, and improving the clinicaloutcomes in such patients. However, despite optimal reperfusiontherapy, morbidity and mortality remain substantial, with about5 to 6% of patients having a subsequent cardiovascular eventby 30 days.2
One treatment strategy that might reduce the size of the infarctand improve the clinical outcomes in these . . . [Full Text of this Article]
Source Information
From the Hatter Cardiovascular Institute and Centre for Cardiology, University College London Hospitals and Medical Schools, London.
This article has been cited by other articles:
Heusch, G.
(2009). No RISK, no ... cardioprotection? A critical perspective. Cardiovasc Res
84: 173-175
[Full Text]
Heusch, G., Schulz, R.
(2009). Neglect of the coronary circulation: some critical remarks on problems in the translation of cardioprotection. Cardiovasc Res
84: 11-14
[Full Text]
Gomez, L., Li, B., Mewton, N., Sanchez, I., Piot, C., Elbaz, M., Ovize, M.
(2009). Inhibition of mitochondrial permeability transition pore opening: translation to patients. Cardiovasc Res
83: 226-233
[Abstract][Full Text]
Venugopal, V., Ludman, A., Yellon, D. M., Hausenloy, D. J.
(2009). 'Conditioning' the heart during surgery. Eur. J. Cardiothorac. Surg.
35: 977-987
[Abstract][Full Text]